MYCN and neuroblastoma: It has been known that increased levels of c-Myc or N-Myc result in the development of drug resistance in multiple cancers, such as NB [17], leukemia [18], endometrial cancer [19], hepatocellular carcinoma (HCC) [20], human small cell lung carcinoma [21], and pancreatic cancer [22].